Surgalign Launches Next Generation Software for its HOLO Portal™ Surgical Guidance System and Expands Surgical Tool Integration to Drive Use Case Adoption
2023年3月20日 - 9:30PM
Surgalign Holdings, Inc. (Nasdaq: SRGA), a global medical
technology company focused on elevating the standard of care by
driving the evolution of digital surgery, today announced the first
major upgrade of the HOLO Portal™ Surgical Guidance System since
the first case was performed in May of 2022. Since launch, the
Company has worked with surgeons to enhance system functionality
and expand use cases in the operating room.
This next generation system from Surgalign
includes over 250 enhancements in software, hardware upgrades, and
integration with new instrumentation, including over 20 new
surgical tools designed for use with HOLO Portal. These
improvements were designed to better support open lumbar pedicle
screw procedures by adding an array of new pedicle preparation
tools and also includes advancements in workflow and setup. The
Company expects these improvements to expand the number of cases
where HOLO Portal can be used, and to save time in existing HOLO
Portal cases.
Terry Rich, President and Chief Executive
Officer of Surgalign, commented, “As part of our limited market
release of HOLO Portal last year, we worked closely with our
surgeon partners to incorporate their feedback from clinical use to
advance HOLO Portal’s capabilities. We expect this release to
increase the utilization of HOLO Portal among both current and
future surgeons, as it better supports screw placement in open
procedures, which represents about 80% of lumbar fusions, while
providing a better workflow and operating environment.
Additionally, we have further upgrades planned which should help
drive further adoption in the second half of the year and into 2024
and beyond.”
Dr. Jaideep Chunduri, a fellowship trained
orthopaedic spine surgeon at Beacon Orthopedics & Sports
Medicine, currently uses HOLO Portal for his procedures at Good
Samaritan Hospital in Cincinnati, Ohio. Dr. Chunduri added, “After
vigorously testing the software in the lab, I am excited to start
using this upgrade in the OR. It will create additional
opportunities to use the system for more of my procedures and make
my current procedures far more efficient. It was a real pleasure
working with fellow HOLO Portal users and the Surgalign team on
this release, and it’s great to see such rapid implementation of
physician feedback.”
All HOLO Portal customers will receive the
upgrade, as HOLO Portal is currently offered with evergreen
upgrades of software and hardware. For more information on HOLO
Portal and our HOLO AI platform, please visit us online at
https://surgalign.com/digital-health/.
About Surgalign Holdings,
Inc.Surgalign Holdings, Inc. is a global medical
technology company committed to the promise of digital health to
drive transformation across the surgical landscape. Uniquely
aligned and resourced to advance the standard of care, the company
is building technologies physicians and other health providers will
look to for what is truly possible for their patients. Surgalign is
focused on developing solutions that predictably deliver superior
clinical and economic outcomes. Surgalign markets products
throughout the United States and in approximately 50 countries
worldwide through an expanding network of top independent
distributors. Surgalign is headquartered in Deerfield, IL, with
commercial, innovation and design centers in San Diego, CA, Warsaw
and Poznan, Poland, and Wurmlingen, Germany. Learn more at
www.surgalign.com and connect on LinkedIn, Twitter and
Instagram.
Forward Looking StatementsThis
press release contains forward-looking statements including,
without limitation, statements relating the intended use of
proceeds from the registered direct offering. These forward-looking
statements are based on management’s current expectations,
estimates and projections about our industry, our management’s
beliefs and certain assumptions made by our management. Words such
as “anticipates,” “expects,” “intends,” “plans,” “believes,”
“seeks,” “estimates,” variations of such words and similar
expressions are intended to identify such forward-looking
statements. Factors that could cause actual results to differ
materially from those forward-looking statements include: i) the
Company’s access to adequate operating cash flow, trade credit,
borrowed funds and equity capital to fund its operations and pay
its obligations as they become due, and the terms on which external
financing may be available, including the impact of adverse trends
or disruption in the global credit and equity markets; (ii) risks
relating to existing or potential litigation or regulatory actions;
(iii) the identification of control deficiencies, including
material weaknesses in internal control over financial reporting;
(iv) general worldwide economic conditions and related
uncertainties; (v) the continued impact of the COVID-19 and the
Company’s attempts at mitigation, particularly in international
markets served by the Company; (vi) the failure by the Company to
identify, develop and successfully implement its strategic
initiatives, particularly with respect to its digital surgery
strategy ; (vii) the reliability of our supply chain; (viii) our
ability to meet obligations, including purchase minimums, under our
vendor and other agreements; (ix) whether or when the demand for
procedures involving our products will increase; (x) our financial
position and results, total revenue, product revenue, gross margin,
and operations; (xi) failure to realize, or unexpected costs in
seeking to realize, the expected benefits of the Holo Surgical Inc.
(“Holo Surgical”) and Inteneural Networks Inc. (“INN”)
acquisitions, including the failure of Holo Surgical’s and INN’s
products and services to be satisfactorily developed or achieve
applicable regulatory approvals or as a result of the failure to
commercialize and distribute its products; (xii) the failure to
effectively integrate Holo Surgical’s and INN’s operations with
those of the Company, including: retention of key personnel; the
effect on relationships with customers, suppliers, and other third
parties; and the diversion of management time and attention to the
integration; (xiii) the number of shares and amount of cash that
will be required in connection with any post-closing milestone
payments, including as a result of changes in the trading price of
the Company’s common stock and their effect on the amount of cash
needed by the Company to fund any post-closing milestone payments
in connection with the acquisitions; (xiv) the continuation of
recent quality issues with respect to our global supply chain and
(xv) the effect and timing of changes in laws or in governmental
regulations. These factors should be considered carefully, and
undue reliance should not be placed on the forward-looking
statements. Each forward-looking statement in this communication
speaks only as of the date of the particular statement.
These forward-looking statements are not
guarantees of future performance and are subject to various risks
and uncertainties, including market and other conditions and the
risks identified in Surgalign’s most recent Annual Report on Form
10-K and other filings with the SEC. Our actual results may differ
materially from the anticipated results reflected in these
forward-looking statements. Copies of Surgalign’s SEC filings may
be obtained without charge by visiting Surgalign’s website
at www.surgalign.com or the SEC’s website
at www.sec.gov. We undertake no obligation to update
these forward-looking statements except as may be required by
law.
Investor Relations and Media Relations
Contact:Glenn WienerEmail: gwiener@surgalign.comTel: +1
917 887 8434
Surgalign (NASDAQ:SRGA)
過去 株価チャート
から 8 2024 まで 9 2024
Surgalign (NASDAQ:SRGA)
過去 株価チャート
から 9 2023 まで 9 2024